Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗

Topics Artificial Intelligence Supply Chain

February 13, 2026

American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Topics Regulatory Compliance

The market is filled with gapping stocks in Friday's session. ↗

February 06, 2026

Via Chartmill

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

Topics ETFs Economy Initial Public Offering

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 06, 2026

Via Chartmill

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗

February 06, 2026

Via Stocktwits

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

February 06, 2026

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

February 06, 2026

From Pulmovant, Inc.

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Preview For Roivant Sciences ↗

November 07, 2025

Via Benzinga

February 06, 2026

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

January 23, 2026

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Via Benzinga

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 11, 2025

Roivant (ROIV) Q2 2026 Earnings Call Transcript

Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗

November 27, 2025

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Looking Into Roivant Sciences Ltd's Recent Short Interest ↗

November 11, 2025

Via Benzinga

November 10, 2025

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 27, 2025

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗

6 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 18, 2025

Via Benzinga

September 17, 2025

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,...

Via Stocktwits

Why Roivant Sciences Stock Is Soaring Today ↗

September 17, 2025

The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.

Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗

September 17, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗

September 17, 2025

The company is working on a treatment for an autoimmune disease that affects the skin and muscles.

Via Investor's Business Daily

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

September 17, 2025

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

September 11, 2025

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 04, 2025

From Pulmovant, Inc.